Table 3.
Entities in the HFPNe model of Figure 6
| Entity Name | Variable (mx) |
| LIN-3(AC) | m1 |
| LET-23 | m2 |
| LIN-3/LET-23 complex | m3 |
| LIN-3/LET-23 dimer | m4 |
| LIN-3/LET-23 dimer{p} | m5 |
| SEM-5 | m6 |
| SEM-5{active} | m7 |
| LET-60 | m8 |
| LET-60{active} | m9 |
| MPK-1 | m10 |
| MPK-1{active}(C) | m11 |
| MPK-1{active}(N) | m12 |
| LIN-1/LIN-31 complex | m13 |
| LIN-31{active} | m14 |
| LIN-1{active} | m15 |
| Vulval gene mRNA | m16 |
| LS mRNA | m17 |
| 1° cell fate | m18 |
| LS molecules(C) | m19 |
| LIN-12/Notch receptor | m20 |
| LIN-12R/LS complex | m21 |
| Cleaved fraction of LIN-12R/LS (extracellular domain) | m22 |
| Intracellular domain of LIN-12/LS complex (C) | m23 |
| Intracellular domain of LIN-12/LS complex (N) | m24 |
| LAG-1 | m25 |
| LST mRNA | m26 |
| LST inhibitors | m27 |
| LIN-3 emanating from hyp7 | m28 |
| LIN-15 in hyp7 | m29 |
| 2° cell fate | m30 |
| Final fate determined by Rule II | m31 |
| Final fate determined by Rule I | m32 |
Table 3: Variable mx ∈ {m1, ⋯, m32} indicates the concentration of each substance that actually takes part in the biological reactions. Initial value represents the initial content of an entity.